Navigation Links
CytoSorbents to Present at the 2014 Rodman & Renshaw Annual Global Investment Conference
Date:9/3/2014

MONMOUTH JUNCTION, N.J., Sept. 3, 2014 /PRNewswire/ -- CytoSorbents Corporation (OTCQB: CTSO) announced that Chief Executive Officer, Dr. Phillip Chan, MD, PhD, will present at the Rodman & Renshaw Annual Global Investment Conference (sponsored by H.C. Wainwright & Co) taking place on September 8-10th in New York City.   CytoSorbents is a critical care immunotherapy company commercializing its CytoSorb® cytokine adsorber to treat patients with life-threatening inflammatory conditions in the intensive care unit in nineteen countries worldwide.

Conference Presentation Details:
Where:  New York Palace Hotel, 455 Madison Avenue, New York, NY 10022
When:  Tuesday, September 9th at 2:05 PM
Room:   Kennedy II Salon (4th Floor)
Webcast:  http://wsw.com/webcast/rrshq24/ctso
Conference Website:  Rodman and Renshaw 16th Annual Global Investment Conference

About CytoSorbents Corporation
CytoSorbents Corporation is a critical care focused immunotherapy company using blood purification to modulate inflammation -- with the goal of preventing or treating multiple organ failure in life-threatening illnesses. Organ failure is the cause of nearly half of all deaths in the intensive care unit, with little to improve clinical outcome. CytoSorb®, the Company's flagship product, is approved in the European Union as a safe and effective extracorporeal cytokine adsorber, designed to reduce the "cytokine storm" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery to try to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure.

CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbents has numerous products under development based upon this unique blood purification technology, protected by 32 issued US patents and multiple applications pending, including HemoDefend™, ContrastSorb, DrugSorb, and others. Additional information is available for download on the Company's website: http://www.cytosorbents.com/

Forward-Looking Statements
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release are not promises or guarantees and are subject to risks and uncertainties that could cause our actual results to differ materially from those anticipated. These statements are based on management's current expectations and assumptions and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements. Actual results may differ materially from those expressed or implied by the statements herein. Risk factors are detailed in the Company's Form 10-K filed with the SEC on March 31, 2014, which is available at http://www.sec.gov.

Logo - http://photos.prnewswire.com/prnh/20140408/MM00899LOGO


'/>"/>
SOURCE CytoSorbents Corporation
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. CytoSorbents Records Another Solid Quarter of Growth in Q2 2014
2. CytoSorbents Expands Distribution to Taiwan with Hemoscien Corporation
3. CytoSorbents Receives Approximately $400,000 in Non-Dilutive Capital from the Sale of Net Operating Loss Carryovers
4. Inovio to Present at Upcoming Investor Conferences
5. Isis Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference
6. RXi Pharmaceuticals to Present at the Rodman & Renshaw 16th Annual Global Investment Conference
7. Relmada Therapeutics to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th, 2014
8. Avanir Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference
9. Abaxis, Inc. to Present at the Morgan Stanley Global Healthcare Conference
10. Volcano Corporation Presentation At Morgan Stanley Conference To Be Webcast
11. Hologic to Present at the Morgan Stanley Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/14/2017)... 14, 2017  ivWatch LLC, a medical device company ... (IV) therapy, is pleased to announce it was the ... Hospital Supplies and Equipment at the 2017 Medical Design ... medtech industry. The award was presented by Medical Device ... Center in New York during ...
(Date:6/11/2017)... 10, 2017  Eli Lilly and Company (NYSE: ... 3 studies of galcanezumab, an investigational treatment for the ... on several key secondary endpoints for galcanezumab compared to ... studies (EVOLVE-1, EVOLVE-2 and REGAIN) will be presented today ... in Boston . ...
(Date:6/8/2017)... LOS ANGELES , June 8, 2017   Responding ... prescription drug oversight and the death of singer Chris ... Commission on Human Rights International offers a free online ...  to better educate consumers and families about psychotropic drug risks. ... Heath Ledger , who died from an accidental overdose, has ...
Breaking Medicine Technology:
(Date:6/23/2017)... ... 2017 , ... Radabaugh & Associates, a locally owned firm ... in North Central West Virginia, is embarking on a cooperative charity drive with ... the region. , The Stepping Stones organization offers a series of personal development ...
(Date:6/22/2017)... (PRWEB) , ... June 22, 2017 , ... ... advisory organization, is pleased to welcome Whipple & Company as its newest Partner ... clear purpose of balancing their clients’ risk while tailoring optimized benefit packages that ...
(Date:6/22/2017)... ... June 22, 2017 , ... The VA ... Maryland Recycling Network has awarded the Baltimore VA Medical Center, a division of ... Award for its efforts to promote waste reduction and promote recycling. Also, ...
(Date:6/20/2017)... ... June 20, 2017 , ... TwelveStone Health Partners, a premier ... private equity firm, has invested $3.35 million in the company. , “We ... Capital offers the smart money, speed to market and accountability we had been ...
(Date:6/20/2017)... FL (PRWEB) , ... June 20, 2017 , ... ... interactive health science curriculum , is pleased to announce a new online course ... accredited online course provides practical insights and evidence-based strategies for achieving optimal well-being ...
Breaking Medicine News(10 mins):